PBYI Stock Risk & Deep Value Analysis
Puma Biotechnology Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About PBYI Stock
We analyzed Puma Biotechnology Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PBYI through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
PBYI Risk Analysis & Red Flags
What Could Go Wrong
Puma Biotechnology's core product, NERLYNX, is experiencing declining new patient enrollments, and Q1 2026 guidance projects a significant revenue drop and a return to net losses. Without any new pipeline assets or clear growth drivers identified, the company risks continued revenue contraction and prolonged unprofitability, potentially leading to further share price erosion and cash burn despite its strong balance sheet.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Q1 2026 guidance projecting significant revenue decline and a net loss after Q4 2025 profitability.
- ⚠
Declining new prescriptions/patient enrollments for the core product, NERLYNX.
- ⚠
Absence of any mention of previously cited pipeline catalysts (e.g., Alisertib) in current market intelligence.
- ⚠
Lack of specific information on total addressable market, competitive landscape, or future strategic vision for growth.
- ⚠
No reported insider buying from key executives, only routine RSU grants to new non-executive employees.
Upcoming Risk Events
- 📅
Q1 2026 earnings confirming or worsening projected net loss and revenue decline
- 📅
Continued decline in NERLYNX new prescriptions and patient enrollments
- 📅
Lack of any future pipeline development or clinical trial updates
When to Reconsider
- 🚪
Exit if quarterly revenue consistently falls below $40 million for two consecutive quarters.
- 🚪
Sell if the company announces further delays or termination of any previously unmentioned pipeline programs.
- 🚪
Consider exit if net losses persist beyond Q1 2026 without clear path to renewed profitability.
Unlock PBYI Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Puma Biotechnology Inc (PBYI) Do?
Market Cap
$307.82M
Sector
Healthcare
Industry
Biotechnology
Employees
172
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Visit Puma Biotechnology Inc WebsiteInvestment Thesis
An investment in Puma Biotechnology at this juncture is a highly speculative bet on a significant and currently unforeseen turnaround in its core NERLYNX business, or the emergence of a new, high-potential pipeline asset that is not currently disclosed. The bull case relies entirely on the company's ability to reverse declining patient enrollment, re-accelerate revenue growth, and identify new, commercially viable indications or drug candidates, leveraging its strong balance sheet.
Is PBYI Stock Undervalued?
Unlock the full AI analysis for PBYI
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
PBYI Price Targets & Strategy
12-Month Target
$8.50
Bull Case
$12.00
Bear Case
$3.50
Valuation Basis
1.5x Price-to-Sales multiple applied to a speculative $300M annualized revenue (recovery to Q4 2025 levels) for 12-month target, reflecting high uncertainty.
Entry Strategy
Given the declining guidance and lack of positive catalysts, a cautious entry strategy would be to dollar-cost average near $5.00 (a potential support zone if negative trends worsen) only if stabilization signs emerge.
Exit Strategy
Take profit at $10-$12 if revenue trajectory reverses positively and profitability stabilizes. Set a stop-loss at $4.00 if Q1 2026 results are worse than projected or further pipeline setbacks occur.
Portfolio Allocation
1-3% for aggressive risk tolerance only. Not suitable for moderate or conservative portfolios at this time.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is PBYI Financially Healthy?
Valuation
P/E Ratio
5.34
Forward P/E
16.87
Price/Book
2.78
Price/Sales
0.98
Profitability
Gross Margin
72.33%
Operating Margin
19.35%
Net Margin
20.35%
Return on Equity
63.24%
EPS
$0.97
Balance Sheet
Current Ratio
1.73
Quick Ratio
1.62
Debt/Equity
0.10
Cash Flow
EBITDA
$57.34M
Other
Beta (Volatility)
1.26
Does PBYI Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Eroding
Moat Sources
1 Identified
The moat, primarily derived from NERLYNX's patent protection and FDA approval, appears to be eroding as evidenced by declining new patient enrollments and increased competitive pressures (implied by lack of market share growth data). Without new pipeline assets, the long-term durability is questionable as the drug ages and faces competition.
Moat Erosion Risks
- •Patent expiry or new generic competition for NERLYNX
- •Development of superior treatments by competitors
- •Limited new indications or market expansion for NERLYNX
PBYI Competitive Moat Analysis
Sign up to see competitive advantages
PBYI Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (No specific data provided to indicate strong bullish or bearish sentiment)
Institutional Sentiment
Neutral (No analyst upgrades/downgrades or specific institutional activity reported beyond a Vanguard internal realignment with 0% ownership)
Insider Activity (Form 4)
Compensation Committee granted 31,625 restricted stock units to 5 new non-executive employees on April 1, 2026, vesting over 3 years. No CEO/CFO purchase or sale activity reported in the last 90 days.
Options Flow
Normal options activity (No specific unusual options flow data was provided).
Earnings Intelligence
Next Earnings
Q1 2026 (Report date not specified)
Surprise Probability
Low (for positive surprise, as Q1 guidance already projects loss and revenue decline. High for negative surprise if results are worse than guidance.)
Historical Earnings Pattern
No specific historical earnings reaction patterns are provided, but given the negative Q1 guidance, a negative market reaction to confirmation of this outlook is likely unless an unexpected positive update emerges.
Key Metrics to Watch
Competitive Position
Top Competitor
Not specified in provided data
Market Share Trend
Losing ground (indicated by declining new prescriptions/patient enrollments for NERLYNX).
Valuation vs Peers
No specific valuation ratios or peer comparisons available in the provided data. Based on current outlook (declining revenue, projected loss), it likely trades at a discount to growth-oriented biotech peers.
Competitive Advantages
- •FDA-approved drug (NERLYNX) for specific cancer indications
- •Strong balance sheet providing financial stability
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive PBYI Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings report (date not specified, but expected to confirm guidance)
- •Potential update on NERLYNX new patient enrollment trends
Medium-Term (6-18 months)
- •No specific medium-term catalysts identified in provided data
- •Potential for new indications or market expansion for NERLYNX (speculative)
Long-Term (18+ months)
- •Discovery or licensing of a new blockbuster drug candidate (highly speculative given no current data)
- •Major shift in cancer treatment paradigms favoring NERLYNX (unlikely without new data)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for PBYI?
- ✓
Any positive updates on clinical trials for new drug candidates or indications for NERLYNX
- ✓
Reversal of declining trends in NERLYNX new prescriptions and patient enrollments
- ✓
Consistent quarterly revenue growth and sustained GAAP profitability
Bull Case Analysis
See what could go right with Premium
Competing with PBYI
See how Puma Biotechnology Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Puma Biotechnology Inc PBYI | $307.8M | 1.7 | 5.3 | $238.1M | 20.3% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $154.6B | 0.2 | 19.9 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Puma Biotechnology Inc Makes Money
Puma Biotechnology is a biopharmaceutical company primarily focused on the development and commercialization of its FDA-approved drug, NERLYNX (neratinib), used for the treatment of certain types of breast cancer. The company generates revenue by selling NERLYNX directly to healthcare providers and through royalties from partners. Its business model relies on the ongoing prescription and patient uptake of NERLYNX, as well as the potential future development of new indications for this drug or other pipeline candidates.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Puma Biotechnology Inc (PBYI)?
As of April 6, 2026, Puma Biotechnology Inc has a DVR Score of 1.7 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Puma Biotechnology Inc?
Puma Biotechnology Inc's market capitalization is approximately $307.8M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Puma Biotechnology Inc use?
PBYI is the ticker symbol for Puma Biotechnology Inc. The company trades on the NMS.
What is the risk level for PBYI stock?
Our analysis rates Puma Biotechnology Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of PBYI?
Puma Biotechnology Inc currently has a price-to-earnings (P/E) ratio of 5.3. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Puma Biotechnology Inc's revenue growing?
Puma Biotechnology Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is PBYI stock profitable?
Puma Biotechnology Inc has a profit margin of 20.3%. This indicates strong profitability.
How often is the PBYI DVR analysis updated?
Our AI-powered analysis of Puma Biotechnology Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 6, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PBYI (Puma Biotechnology Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.